Continuing with its strategy of making acquisitions and thereby expanding its portfolio Valeant Pharmaceuticals International, Inc. (NYSE:VRX) recently purchased US-based, privately owned specialty pharmaceutical company, Pedinol Pharmacal, Inc.
The deal, expected to boost Valeant’s earnings immediately, is worth less than one and half times the sales recorded by Pedinol Pharma, a drug maker focused on foot-related disorders, in 2011. Pedinol Pharma’s 2011 revenues came in at approximately $18 … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards